Imprecise excision of P{GT1}BG01736 has removed the entire Grip coding region.
adult abdomen (with Gripex122)
adult head (with Gripex122)
At stages 13-14, approximately 40% of muscles are normal in mutant embryos, approximately 50% have abnormal projections and approximately 10% are rounded. Most muscles recover as embryogenesis proceeds in the mutant embryos, such that at stage 16, more than 80% of muscles are normal, while the remainder either have abnormal projections or are rounded.
Muscle VL1 exhibits abnormal morphology in approximately 50% of cases in Gripex36 embryos, either occasionally showing a rounded morphology or, more commonly, failing to span the entire abdominal segment.
Gripex36 mutants exhibit abnormal muscle patterning.
Gripex36 mutants show defects in ventrolateral muscle (VLM) morphogenesis. Instead of forming a single polarized muscle projection, the VLMs of Gripex36 mutants frequently send out two or more projections in essentially randomized directions. When the
muscle guidance period ceases, these VLMs typically form ball-like structures that extend over only about half of a hemisegment without reaching their target tendon cell. Lateral transverse muscles (LTMs) appear unaffected.
Expression of GripΔ1-3.Scer\UAS, under the control of Scer\GAL4twi.PG leads to very strong defects in lateral transverse muscles (LTMs) Gripex36 and Gripex36/+ backgrounds. LTM defects include splitting into multiple projections, bending away from their target tendon cells and forming aberrant, integrin positive attachments in ectopic positions. These defects appear qualitatively very similar when scored in embryos or in larvae. Scer\GAL4twi.PG>GripΔ1-3.Scer\UAS expression in a Gripex36 or Gripex36/+ background results in slight ventrolateral muscle (VLM) defects.
Gripex122/Y mutant animals exhibit abnormal patterning of the ventral longitudinal muscles (VLMs). The VLMs of the mutants appear rounded instead of stretched between the attachment sites at the segment borders. Affected VLMs position themselves randomly more at either the anterior or posterior end of the segment borders. IN weaker cases, while still attached to both segment borders, the mutant VLMs appear irregularly shaped and do not align in register at the segment borders. Over 95% of all VLMs 6/7 are affected Hemizygous and Gripex122/Gripex36 animals develop into larvae which maintain the defective VLM pattern seen in embryos. Within these animals, the embryonically affected muscles grow and elongate throughout larval development. No sign of muscle degeneration is recognisable. affected VLMs produce ectopic intrasegmental attachments. These attachments form at the inner layer of muscles and not at the epidermis. Both in embryos and in larvae, even the most affected mutant VLMs form multiple extensions. Defective VLMs also have normal organisation of the contractile apparatus. Adult escapers show a shrunken abdomen and defective head posture. No other defects, in particular no signs of general impairment of cell adhesion, are observed in the animals.
Gripex36 has ventral longitudinal muscle cell phenotype, enhanceable by ed[+]/ed1X5
Gripex36 has ventral longitudinal muscle cell phenotype, enhanceable by edUAS.cBa/Scer\GAL4twi.PG
Gripex36 is an enhancer of lateral transverse muscle cell phenotype of Scer\GAL4twi.PG, edUAS.cBa
Gripex36, ed[+]/ed1X5 has lateral transverse muscle cell phenotype
Gripex36, ed1X5/+ embryos exhibit more severe VLM defects than Gripex36 embryos. In severe cases, the double mutants exhibit completely deranged somatic musculature, where muscle identification is no longer possible. Lateral transverse muscles are defective in Gripex36/Y; ed1X5/+ embryos, while these muscles appear normal in both single heterozygote.
Expression of edScer\UAS.cBa, under the control of Scer\GAL4twi.PG, in a Gripex36 background, greatly enhances the muscle defects of Gripex36 embryos; ventrolateral muscles are more severely deranged and often appear to adhere to other muscles, whereas lateral transverse muscles split.
Gripex36 is rescued by Scer\GAL4twi.PG/GripUAS.cSa
Gripex36 is rescued by Scer\GAL4twi.PG/GripΔ4-5.UAS
Gripex36 is rescued by GripΔ4-5L.UAS/Scer\GAL4twi.PG
Gripex36 is rescued by Scer\GAL4twi.PG/GripΔint.UAS
Gripex36 is rescued by Scer\GAL4twi.PG/Gripx1.UAS
Gripex36 is rescued by Scer\GAL4twi.PG/Gripx2.UAS
Gripex36 is rescued by Scer\GAL4twi.PG/Gripx6.UAS
Gripex36 is rescued by Scer\GAL4how-24B/GripUAS.cSa
Gripex36 is rescued by Scer\GAL4twi.PG/GripUAS.cSa
Gripex36 is partially rescued by Scer\GAL4twi.PG/GripΔ1-3.UAS
Gripex36 is partially rescued by Scer\GAL4twi.PG/GripΔ6-7.UAS
Gripex36 is partially rescued by Scer\GAL4twi.PG/Gripx3.UAS
Gripex36 is partially rescued by Scer\GAL4twi.PG/Gripx7.UAS
Gripex36 is partially rescued by Scer\GAL4twi.PG/GripΔ1-3x7.UAS
Gripex36 is not rescued by Scer\GAL4twi.PG/GripΔ4-7.UAS
Gripex36 is not rescued by GripΔ1-5.UAS/Scer\GAL4twi.PG
Gripex36 is not rescued by Scer\GAL4en-e16E/GripUAS.cSa
Gripex36 is not rescued by Scer\GAL4sr-md710/GripUAS.cSa
Expression of GripΔ6-7.Scer\UAS or Gripx7.Scer\UAS under the control of Scer\GAL4twi.PG results in a partial rescue of the Gripex36 ventral longitudinal muscle (VLM) phenotype, with many VLMs appearing atypically round. The Gripx3.Scer\UAS transgene also leads to a partial rescue of this phenotype.